Delaware
|
22-2413505
|
(State
or Other Jurisdiction of
|
(IRS
Employer Identification Number)
|
Incorporation
or Organization)
|
2001Route 46 Parsippany, NJ
|
07054
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Large
accelerated filer
|
¨
|
Accelerated
filer
|
¨
|
Non-accelerated
filer
|
¨ (Do not check if
a smaller reporting company)
|
Smaller
reporting company
|
x
|
Page
|
|
PART
I. FINANCIAL INFORMATION
|
|
Item
1. Financial Statements
|
3
|
Condensed
Consolidated Balance Sheets as of March 31, 2009 (Unaudited) and December
31, 2008
|
4
|
Condensed
Consolidated Statements of Operations for the Three Months
Ended
|
|
March
31, 2009 and 2008 (Unaudited) and for the period from January 1, 2008
through
|
|
March
31, 2009 (development stage period) (Unaudited)
|
5
|
Condensed
Consolidated Statements of Cash Flows for the Three Months
Ended
|
|
March
31, 2009 and 2008 (Unaudited) and for the period from January 1, 2008
through
|
|
March
31, 2009 (development stage period) (Unaudited)
|
6
|
Notes
to Condensed Consolidated Financial Statements (Unaudited)
|
7
|
Item
2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
|
9
|
Item
3. Quantitative and Qualitative Disclosure about Market
Risk
|
11
|
Item
4T. Controls and Procedures
|
11
|
PART
II. OTHER INFORMATION
|
|
Item
1. Legal Proceedings
|
12
|
Item
2. Unregistered Sales of Equity Securities and Use of
Proceeds
|
12
|
Item
6. Exhibits
|
13
|
SIGNATURES
|
14
|
March 31, 2009
(Unaudited)
|
December 31, 2008
|
|||||||
Assets
|
||||||||
Current
assets
|
||||||||
Cash
and cash equivalents
|
$ | 1,247,173 | $ | 1,160,587 | ||||
Restricted
cash
|
- | 321,329 | ||||||
Other
receivables
|
1,033 | 1,033 | ||||||
Prepaid
expenses and other current assets
|
534 | 3,239 | ||||||
Total
assets
|
$ | 1,248,740 | $ | 1,486,188 | ||||
Liabilities
and Stockholders’ Equity
|
||||||||
Current
liabilities
|
||||||||
Accounts
payable
|
$ | 146,120 | $ | 115,220 | ||||
Accrued
expenses
|
140,034 | 152,853 | ||||||
Accrued
payroll and related liabilities
|
17,262 | 17,262 | ||||||
Accrued
interest – related party
|
15,814 | 15,814 | ||||||
Total
liabilities
|
319,230 | 301,149 | ||||||
Commitments
and contingencies
|
||||||||
Stockholders’
Equity
|
||||||||
Preferred
stock – par value $.001 per share; authorized 1,000,000 shares; 200,000
shares designated Series A; 155,557 shares issued and outstanding
(aggregate liquidation preference $280,003)
|
156 | 156 | ||||||
Common
stock – par value $.001 per share; authorized 750,000,000 shares;
33,056,161 shares issued and outstanding
|
33,057 | 33,057 | ||||||
Additional
paid-in capital
|
45,873,892 | 45,873,145 | ||||||
Accumulated
deficit
|
(44,721,320 | ) | (44,053,887 | ) | ||||
Deficit
accumulated during the development stage
|
(256,275 | ) | (667,432 | ) | ||||
Total
stockholders’ equity
|
929,510 | 1,185,039 | ||||||
Total
liabilities and stockholders’ equity
|
$ | 1,248,740 | $ | 1,486,188 |
For the Three Months
Ended March 31, 2009
|
For the Three Months
Ended March 31, 2008
|
For the period from
January 1, 2008
through March 31,
2009 (development
stage period)
|
||||||||||
Net
sales
|
$ | - | $ | - | $ | - | ||||||
General
and administrative expenses
|
259,309 | 230,353 | 954,462 | |||||||||
Loss
from operations
|
(259,309 | ) | (230,353 | ) | (954,462 | ) | ||||||
Interest
income/(expense)
|
3,033 | 15,644 | 45,448 | |||||||||
Loss
before income tax
|
(256,276 | ) | (214,709 | ) | (909,014 | ) | ||||||
Income
tax (expense)
|
- | - | (14,694 | ) | ||||||||
Net
loss
|
$ | (256,276 | ) | $ | (214,709 | ) | $ | (923,708 | ) | |||
Per
share data:
|
||||||||||||
Net
loss per common share
|
||||||||||||
Basic
and diluted
|
$ | (0.00 | ) | $ | (0.01 | ) | ||||||
Weighted
average number of common shares outstanding
|
||||||||||||
Basic
and diluted
|
33,056,161 | 33,047,161 |
For the Three Months
Ended March 31, 2009
|
For the Three Months
Ended March 31, 2008
|
For the period from
January 1, 2008
through March 31,
2009 (development
stage period)
|
||||||||||
Cash
flows from operating activities
|
||||||||||||
Net
loss
|
$ | (256,276 | ) | $ | (214,709 | ) | $ | (923,708 | ) | |||
Adjustments
to reconcile net loss to net cash from operating
activities:
|
||||||||||||
Non-cash
stock-based compensation
|
747 | 1,929 | 11,056 | |||||||||
Interest
income on restricted cash
|
(183 | ) | (1,460 | ) | (1,512 | ) | ||||||
Changes
in operating assets and liabilities:
|
||||||||||||
Other
receivable
|
- | 355,663 | 396,835 | |||||||||
Prepaid
expenses and other current assets
|
2,705 | 108 | 8,994 | |||||||||
Accounts
payable
|
30,900 | (156,657 | ) | (187,760 | ) | |||||||
Accrued
expenses
|
(12,819 | ) | (52,508 | ) | (24,214 | ) | ||||||
Accrued
payroll and related liabilities
|
- | (553,736 | ) | (879,986 | ) | |||||||
Net
cash used in operating activities
|
(234,926 | ) | (621,370 | ) | (1,600,295 | ) | ||||||
Cash
flows from investing activities
|
||||||||||||
Release
of restricted cash
|
321,512 | - | 321,512 | |||||||||
Net
cash provided by investing activities
|
321,512 | - | 321,512 | |||||||||
Cash
flows from financing activities
|
||||||||||||
Proceeds
from the exercise of stock options
|
- | - | 315 | |||||||||
Net
cash provided by financing activities
|
- | - | 315 | |||||||||
Net
increase(decrease) in cash and cash equivalents
|
86,586 | (621,370 | ) | (1,278,468 | ) | |||||||
Cash
and cash equivalents – beginning of period
|
1,160,587 | 2,525,641 | 2,525,641 | |||||||||
Cash
and cash equivalents – end of period
|
$ | 1,247,173 | $ | 1,904,271 | $ | 1,247,173 |
|
·
|
our
ability to complete a combination with one or more target
businesses;
|
|
·
|
our
success in retaining or recruiting, or changes required in, our officers
or directors prior to or following a business
combination;
|
|
·
|
our
potential inability to obtain additional financing to complete a business
combination;
|
|
·
|
a
limited pool of prospective target
businesses;
|
|
·
|
a
potential change in control if we acquire one or more target businesses
for stock;
|
|
·
|
our
public securities’ limited liquidity and trading;
and
|
|
·
|
our
ongoing financial performance.
|
31.1
|
*
|
Certification
of Chief Executive Officer pursuant to Securities Exchange Act Rule
13a-14(a)
|
31.2
|
*
|
Certification
of Chief Financial Officer pursuant to Securities Exchange Act Rule
13a-14(a)
|
32.1
|
*
|
Certification
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of
The Sarbanes-Oxley Act of 2002, of Chief Executive
Officer
|
32.2
|
*
|
Certification
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of
The Sarbanes-Oxley Act of 2002, of Chief Financial
Officer
|
CLACENDIX,
INC.
|
/S/ Norman E. Corn
|
Norman
E. Corn, Chief Executive Officer
|
/S/ Patrick E. Delaney
|
Patrick
E. Delaney, Chief Financial
Officer
|
31.1
|
*
|
Certification
of Chief Executive Officer pursuant to Securities Exchange Act Rule
13a-14(a)
|
31.2
|
*
|
Certification
of Chief Financial Officer pursuant to Securities Exchange Act Rule
13a-14(a)
|
32.1
|
*
|
Certification
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of
The Sarbanes-Oxley Act of 2002, of Chief Executive
Officer
|
32.2
|
*
|
Certification
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of
The Sarbanes-Oxley Act of 2002, of Chief Financial
Officer
|